Oocytes

The human oocyte is one of the most remarkable cells in the body from an aging standpoint: it can sit in meiotic arrest for up to ~50 years — from fetal formation to perimenopausal ovulation — without being replaced or renewed. The primordial follicle pool is established before birth and is fixed and non-renewing throughout postnatal life (the dominant view; see Limitations for the contested oogonial stem cell hypothesis). This extreme longevity-in-arrest means the oocyte must maintain chromosomal cohesion, mitochondrial integrity, and proteostasis across a multi-decade pause — a challenge that fails with increasing frequency in the fourth decade of life. The resulting rise in meiotic errors is the mechanistic basis of the well-documented maternal age effect on miscarriage rates, Down syndrome incidence, and IVF outcomes.

Oocytes are terminal gametes, not self-renewing. They are defined by their molecular identity rather than classical surface CD markers; canonical markers are oocyte-specific transcription factors and secreted proteins including GDF9, BMP15, NOBOX, FIGLA, DAZL, and the zona pellucida glycoproteins ZP1/ZP2/ZP3.

Identity and markers

Unlike hematopoietic or muscle stem cells, oocytes lack canonical surface CD markers suitable for flow cytometric isolation. Identity is established by a suite of oocyte-specific transcription factors and secreted proteins:

Marker	Mouse	Human	Function
GDF9 (Growth Differentiation Factor 9)	Gdf9+	GDF9+	Paracrine signal to granulosa cells; essential for folliculogenesis
BMP15 (Bone Morphogenetic Protein 15)	Bmp15+	BMP15+	Paracrine; promotes granulosa proliferation and differentiation
NOBOX	Nobox+	NOBOX+	Homeobox TF; oogenesis master regulator; mutations → primary ovarian insufficiency
FIGLA	Figla+	FIGLA+	bHLH TF; required for zona pellucida gene expression
DAZL	Dazl+	DAZL+	RNA-binding; germ cell specification and meiotic entry
ZP1 / ZP2 / ZP3	Zp1/2/3+	ZP1/2/3+	Zona pellucida structural glycoproteins; species-specific sperm binding

Note: These markers distinguish oocytes from surrounding granulosa cells and other ovarian somatic cells; they are used for immunohistochemical localization rather than FACS isolation. The oocyte proteome is derived almost entirely from mRNA stores translated during maturation, making transcriptomic rather than proteomic profiling the primary molecular characterization tool.

The full meiotic arrest-to-ovulation sequence produces distinct cell states:

Primordial oocyte (dictyate arrest): arrested in prophase I, diplotene stage. The primary aging substrate — this is the state that can persist for decades.
Primary oocyte: resumes meiosis I after LH surge; completes first asymmetric division → secondary oocyte + first polar body.
Secondary oocyte (mature egg): arrested in metaphase II; released at ovulation; completes meiosis II only upon fertilization.

The meiotic arrest problem

The dictyate arrest is the central biological peculiarity that makes the oocyte uniquely susceptible to aging. During fetal oogenesis, cohesin complexes are loaded onto chromosomes — a process that is completed before birth and is not substantially repeated postnatally. The cohesin rings that hold sister chromatids and bivalent homologs together at ovulation in a 40-year-old woman are, in principle, the same molecular structures installed in the fetal ovary approximately 40 years earlier ¹.

This “cohesin non-renewal” model is the leading mechanistic explanation for the maternal age effect on aneuploidy ² ³. Unlike mitotic cells, which reload cohesin at each cell cycle, the oocyte cannot replenish cohesin during arrest. Protein turnover and degradation over decades reduces the effective cohesin load holding chromosomes together, leading to premature centromere separation during meiosis I.

Aging mechanisms

1. Cohesin deterioration — the molecular basis of maternal age aneuploidy

Meiosis-specific cohesins (REC8, SMC1B, STAG3) and the centromere-protective shugoshin protein SGOL2 are loaded during fetal oogenesis and are progressively lost over the reproductive lifespan. Key evidence:

Mouse models: Chiang et al. 2010 (Current Biology) directly demonstrated that oocytes from aged mice (16–19 months, equivalent to perimenopausal women ~38–45 years) have severely reduced chromosome-associated REC8 at centromeres and increased interkinetochore distances compared to young mice (6–14 weeks). Counting chromosome segregation outcomes in 27 young and 36 old oocytes, about 90% of age-related aneuploidies seen in old eggs were consistent with weakened centromere cohesion as the underlying cause — including improper kinetochore biorientation in MI and premature chromatid separation ⁴. Revenkova et al. 2010 confirmed the “load-early-only” hypothesis in mouse, showing that SMC1β cohesin expressed only during fetal dictyate stages is sufficient for lifetime fertility — but its gradual depletion is not corrected by postnatal expression ¹.

Human evidence: Tsutsumi et al. 2014 (PLoS ONE) directly measured meiosis-specific cohesin proteins (REC8, SMC1B) in human ovarian tissue sections from 8 women aged 19–49 years. In per-oocyte comparisons between grouped younger (≤29 y; mean 23.3 ± 4.3 y) and older women (≥40 y; mean 42.5 ± 4.4 y), REC8 and SMC1B signal intensities were significantly reduced by approximately 24% and 38%, respectively (p < 0.01, Student’s t-test), providing the first direct human protein-level evidence for the cohesin depletion model. Both proteins showed negative linear correlation with age across all samples (R² = 0.70 for REC8, R² = 0.62 for SMC1B). The mitotic cohesins (SMC3, RAD21, SMC1A) did not significantly change with age ⁵.

Downstream structural consequence: Zielinska et al. 2019 (Current Biology) showed that partial cohesin loss triggers centromere decompaction and kinetochore fragmentation. Using super-resolution microscopy across 35,700 meiotic kinetochores from mouse, pig, and human MII eggs, they found that fragmentation affected over 30% of MII kinetochores in aged mice (60+ weeks) and older women (>34 years), compared to predominantly compact kinetochores in young eggs. In aged mice (60+ weeks, n=29 mice, n=6,687 kinetochores), approximately 60% of kinetochores were fragmented. In older women (>34 y, n=32 MII eggs), approximately 40% of kinetochores were fragmented versus ~25% in younger women (≤33 y, n=17 MII eggs; p < 0.01). Fragmented kinetochores frequently formed incorrect (merotelic) microtubule attachments, directly linking the structural defect to non-disjunction ⁶.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes
Replicated in humans?	yes — Tsutsumi 2014; epidemiological aneuploidy data robust

The downstream consequence at the population level is profound: the aneuploidy rate in oocytes from women under 35 is approximately 10–25%; by age 40–42 it rises to 40–60%; and by 43–44 it can exceed 75% in IVF cohorts ³. These rates drive the well-characterized maternal age effect on miscarriage (largely due to lethal trisomies) and on trisomy 21 (Down syndrome), the most common chromosomal cause of intellectual disability.

2. Spindle assembly checkpoint weakening

The spindle assembly checkpoint (SAC) is the cell-cycle surveillance mechanism that should prevent progression through meiosis when chromosomes are incorrectly attached to spindle microtubules. Evidence suggests the SAC is inherently less stringent in oocyte meiosis-II than in somatic mitosis, and that this structural weakness — combined with age-related cohesion loss — produces a catastrophic failure mode.

Mihajlović et al. 2023 (EMBO Reports) demonstrated that the SAC “is insensitive in meiosis-II oocytes” such that misaligned chromosomes fail to halt cell division; in younger oocytes this is buffered by intact cohesion, but in aged oocytes where cohesin has declined, premature centromere separation generates widespread misalignment that the SAC cannot detect and arrest ⁷. This two-hit model (cohesin loss + checkpoint insufficiency) explains the steep age-dependence of aneuploidy.

3. Mitochondrial aging and energetic failure

The oocyte is unusual in its mitochondrial biology: it carries the largest mtDNA copy number of any cell in the body (~100,000–500,000 copies in mature human oocytes) and its mitochondria are in a specialized, low-cristae-density morphological state during arrest, becoming more active and morphologically mature during meiotic resumption. Spindle assembly and chromosome segregation are ATP-demanding processes that depend critically on oocyte mitochondrial output.

Pasquariello et al. 2019 (Biology of Reproduction) characterized aging-associated mitochondrial changes in both mouse and human oocytes: aged mouse oocytes had reduced mtDNA copy number and mitochondrial membrane potential, with higher reactive oxygen species levels and increased spindle abnormality rates. Paradoxically, human oocytes from advanced maternal age women showed higher mtDNA copy numbers but lower mitochondrial function, suggesting compensatory replication masking functional decline ⁸. no-fulltext-access — specific quantitative values (n per group, copy-number magnitude, ROS fold-change) not verified against source figures; paper is closed-access. This energetic insufficiency directly impairs spindle assembly fidelity, linking mitochondrial-dysfunction to the chromosome segregation errors described above.

mtDNA mutation accumulation in oocytes over the reproductive lifespan is also a concern: oocyte mtDNA is the exclusive maternal inheritance source for all offspring, meaning aging-associated somatic mtDNA mutations in oocytes have multigenerational implications ⁹. needs-replication — the actual mutation burden in aged human oocytes vs younger oocytes has not been comprehensively quantified by deep-sequencing across a large cohort.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes
Replicated in humans?	in-progress — human data is limited; IVF-based sampling bias affects cohort composition

4. DNA damage accumulation and repair decline

Double-strand breaks (DSBs) accumulate in primordial follicle oocytes with age, alongside declining expression of critical DNA repair genes. The BRCA1 pathway, which coordinates homologous recombination repair and meiotic spindle assembly checkpoint function, appears particularly important.

Titus et al. 2013 (Science Translational Medicine) showed that young women carrying BRCA1 mutations have lower anti-Müllerian hormone (AMH) levels — a biomarker of ovarian reserve — compared to BRCA1-wild-type controls, indicating that BRCA1-dependent DSB repair is required for maintaining primordial follicle pool viability ¹⁰. DSB accumulation in primordial follicles with age was directly observed in their mouse studies. Turan and Oktay 2020 (Human Reproduction Update) synthesized the mechanistic pathway: “BRCA-related ATM-mediated DNA repair function emerges as a likely regulator of ovarian aging,” framing DSB repair efficiency as a regulator of the rate of primordial follicle attrition with age ¹¹.

This connects genomic-instability at the oocyte level to the clinical endpoint of diminished ovarian reserve — the measurable decline in follicle pool size that precedes menopause and is detectable by AMH and antral follicle count (AFC) measurements.

Dimension	Status
Pathway conserved in humans?	yes — BRCA1 mutations are the key human evidence
Phenotype conserved in humans?	yes
Replicated in humans?	yes (AMH studies); mechanistic detail requires model-system work

5. Oxidative stress in the follicular microenvironment

The follicular fluid surrounding the developing oocyte is the immediate microenvironment and reflects systemic oxidative stress. Reactive oxygen species (ROS) increase with advancing maternal age in follicular fluid, correlating with reduced oocyte quality and fertilization rates. Mitochondrial dysfunction (above) is both a source and a target of oxidative damage — creating a feedforward loop in aging oocytes.

Antioxidant interventions (CoQ10, melatonin, myo-inositol, vitamins) have been investigated in the context of diminished ovarian reserve, with a 2024 meta-analysis of 20 randomized clinical trials (2,617 participants) finding that antioxidants increased clinical pregnancy rate (OR 1.55; 95% CI 1.18–2.04; p = 0.002; 20 RCTs, 2,218 participants; moderate-quality evidence) and number of retrieved oocytes (MD 0.98 higher; p < 0.0001; 15 RCTs, 1,734 participants; moderate-quality evidence) and high-quality embryo numbers (MD 0.47; p = 0.003; 12 RCTs, 1,341 participants; moderate-quality evidence) ¹². Notably, live birth rate showed no statistically significant improvement (OR 1.05; 95% CI 0.80–1.37; p = 0.74; 7 RCTs, 1,224 participants; low-quality evidence). CoQ10 was identified as the most effective antioxidant type; subgroup analysis found the optimal CoQ10 regimen for improving pregnancy rate to be 30 mg/d for 3 months before controlled ovarian stimulation. These data are the highest-tier human evidence for IVF-cycle parameters, but the primary endpoint of live birth was not improved, and the evidence quality was rated low to moderate. long-term-unknown

Bidirectional oocyte-granulosa communication

The oocyte does not age in isolation — it is embedded within a follicle whose granulosa-cells provide essential metabolic and signaling support. Bidirectional communication occurs through:

Gap junctions (connexin 37/43-containing) via transzonal projections that physically link cumulus granulosa cells to the oocyte plasma membrane, enabling direct metabolite and second-messenger transfer.
Paracrine signaling: Oocyte-secreted GDF9 and BMP15 drive granulosa cell proliferation, steroidogenesis, and LH receptor expression. Granulosa-secreted factors (AMH, activin, estradiol, KIT ligand) regulate follicle activation and oocyte meiotic competence.

With aging, transzonal projection density decreases and gap-junction coupling is reduced, impairing the oocyte’s access to the energy and signaling precursors supplied by cumulus cells ¹³. Elevated FSH (which rises with age as ovarian reserve declines) may override AMH-mediated protective gating, paradoxically accelerating follicle activation and pool depletion — a vicious cycle where FSH-driven acceleration of folliculogenesis depletes the reserve faster.

The fixed follicle pool and the oogonial stem cell controversy

The classical dogma — established across decades of ovarian biology — holds that the primordial follicle pool is established during fetal life and is not renewed postnatally. Total follicle number at birth in humans is estimated at ~1–2 million; this declines to ~300,000 at puberty, and ~1,000 at menopause, with only ~400–500 follicles ever completing ovulation across the reproductive lifespan. The remainder undergo atresia.

In 2004, Johnson et al. claimed that bone marrow-derived oogonial stem cells (OSCs) could regenerate the oocyte pool in adult mice — a claim that would overturn the fixed-pool model if confirmed. The OSC hypothesis has been actively debated since. Current status: contradictory-evidence

Against OSCs as physiologically relevant: Zarate-Garcia et al. 2016 (Scientific Reports) showed that DDX4-sorted cells from human ovaries are neither DDX4-surface-positive nor germ cells, challenging the original isolation method ¹⁴. Most reproductive biologists treat the fixed-pool model as the default for clinical practice.
Contested OSC claims: Some OSC studies report in-vitro differentiation into oocyte-like cells and live offspring in rodents; clinical significance in humans unproven; Grieve et al. 2015 (Maturitas) concluded “no evidence that they contribute to the primordial follicle pool” ¹⁵.
Current consensus for this wiki: The primordial follicle pool is treated as non-renewing pending resolution of the OSC debate. The aging trajectory of the oocyte is therefore one of inevitable depletion and quality decline rather than failed regeneration.

Proteostasis and the long-lived proteome

Because oocytes are arrested for decades without substantial protein turnover at some loci, they accumulate long-lived proteins (LLPs) — particularly in the zona pellucida (ZP2 is an LLP), nuclear pore complexes, and histone-containing chromatin. Loss-of-proteostasis in the aging oocyte manifests as:

Accumulation of protein aggregates in aged oocytes (detected by aggresome staining in mouse studies). needs-human-replication
Declining proteasome activity in oocytes from aged mice; impaired clearance of meiotic regulatory proteins.
Translational fidelity decline with age — a recently proposed mechanism involving ribosomal integrity loss that may generate error-prone proteins during the rapid burst of translation accompanying meiotic resumption ¹⁶.

Hallmark connections

Hallmark	Mechanism in oocytes
genomic-instability	Cohesin depletion during arrest → chromosome misattachment and aneuploidy; DSB accumulation in primordial follicles with age; BRCA1/ATM pathway decline
mitochondrial-dysfunction	mtDNA copy number and function changes; reduced ATP for spindle assembly; ROS elevation in aged follicular fluid
loss-of-proteostasis	Long-lived protein accumulation; proteasome decline; translational fidelity loss during meiotic resumption
cellular-senescence	Indirect: aging granulosa cells and the follicular microenvironment show SASP-like features; whether oocytes themselves become senescent is contested (they are post-mitotic during arrest) unsourced

Therapeutic and intervention context

Oocyte cryopreservation

Egg freezing (vitrification) allows banking oocytes from younger ages, effectively “pausing” oocyte aging at the point of collection. This is currently the most clinically validated strategy for preserving fertility against reproductive aging. The cohesin depletion and mitochondrial decline that accumulate with age are avoided when oocytes are collected and vitrified at a younger chronological age.

Antioxidant supplementation

CoQ10 (as above, coq10 if a page exists) is the best-evidenced antioxidant for improving IVF-cycle parameters in diminished-ovarian-reserve patients, with a 2024 meta-analysis (20 RCTs, 2,617 participants) showing improved clinical pregnancy rate (OR 1.55) and oocyte retrieval numbers, though live birth rate was not significantly improved (OR 1.05, p = 0.74) ¹². Whether it slows the underlying aging mechanisms (rather than improving acute cycle outcomes) is unknown. no-mechanism for the in-vivo cohesin/mtDNA protection aspect.

Mitochondrial/ooplasmic transfer

Ooplasmic transfer (injection of cytoplasm from young donor eggs into older recipient oocytes) was performed experimentally in the late 1990s and resulted in live births; it was halted by FDA due to concerns about heteroplasmy in offspring. A related approach — transfer of donor mitochondria — is under investigation as a means to restore ATP-generating capacity in aged oocytes. long-term-unknown; not FDA-approved; preliminary data only. needs-replication

In-vitro follicle maturation and artificial ovarian tissue

Systems to mature primordial follicles in vitro are in development; if the primordial follicle pool could be matured on demand, age-related quality decline in the already-arrested population would become the dominant (and potentially addressable) problem. These remain preclinical research approaches as of 2026.

Limitations and gaps

#gap/contradictory-evidence — The oogonial stem cell (OSC) controversy is not resolved. If postnatal oocyte regeneration occurs at any physiologically meaningful scale, the fixed-pool model that underlies much of reproductive aging theory requires revision.
#gap/needs-human-replication — Most mechanistic data on cohesin protein levels, SAC function, and proteostasis decline come from mouse models. Human oocyte studies are severely limited by tissue access (ethically discarded IVF oocytes are the primary source, introducing sampling bias toward women undergoing ART).
#gap/needs-replication — mtDNA mutation burden in aged vs young oocytes has not been quantified by deep-sequencing across a large unbiased human cohort.
#gap/long-term-unknown — Mitochondrial/ooplasmic transfer outcomes have not been followed sufficiently long to assess offspring metabolic and developmental health.
#gap/no-mechanism — Why cohesin degradation rate varies between women (explaining differences in reproductive aging trajectories at the same chronological age) is not understood; genetic, environmental, and metabolic modifiers are hypothesized but not established.
#gap/dose-response-unclear — Optimal antioxidant protocols (dose, timing, duration) for protecting oocyte quality in vivo are not established; existing RCT data are primarily IVF-cycle endpoints.
#gap/unsourced — Senescence in the oocyte itself (vs the follicular microenvironment) requires dedicated citation; current evidence is from somatic follicular cells, not oocytes.
#gap/needs-canonical-id — GDF9, BMP15, NOBOX, FIGLA, DAZL protein pages do not yet exist in this wiki; the wikilinks below are implicit stubs.

Footnotes

doi:10.1016/j.cub.2010.08.024 · Revenkova E, Herrmann K, Adelfalk C, Jessberger R · Current Biology 2010;20(17):1529–1533 · in-vivo (mouse genetic model) · demonstrates cohesin loaded only in fetal dictyate provides full reproductive lifespan fertility; postnatal loading not required or occurring · archive status: pending ↩ ↩²
doi:10.1101/cshperspect.a017970 · Herbert M, Kalleas D, Cooney D, Lamb M, Lister L · Cold Spring Harbor Perspectives in Biology 2015 · review · comprehensive synthesis of cohesin loss, recombination failure, and maternal age effect on trisomy births · archive status: pending ↩
doi:10.1016/j.mrrev.2020.108320 · Mikwar M, MacFarlane AJ, Marchetti F · Mutation Research/Reviews in Mutation Research 2020;785:108320 · review · model: mouse + human · identifies cohesin deterioration, SAC disregulation, mitochondrial dysfunction as leading mechanisms of maternal-age aneuploidy · archive status: not_oa ↩ ↩²
doi:10.1016/j.cub.2010.06.069 · Chiang T, Duncan FE, Schindler K, Schultz RM, Lampson MA · Current Biology 2010;20(17):1522–1528 · in-vivo (natural aging mouse model) + live imaging · n=27 young (6–14 wk) and 36 old (16–19 mo) mouse oocytes for live-imaging anaphase I + MII chromosome counting; n=80 oocytes/lane for western blot (REC8 total levels); additional cohorts for IKD measurements · primary evidence that weakened centromere cohesion explains ~90% of age-related oocyte aneuploidies; chromosome-associated REC8 severely reduced in aged oocytes while total REC8 is constant, demonstrating chromosome loss rather than reduced synthesis · archive status: downloaded ↩
doi:10.1371/journal.pone.0096710 · Tsutsumi M, Fujiwara R, Nishizawa H, Ito M, Kogo H et al. · PLoS ONE 2014;9(5):e96710 · observational · n=8 women aged 19–49 years (ovarian tissue from tumor surgery normal regions); younger group ≤29 y (mean 23.3 ± 4.3 y), older group ≥40 y (mean 42.5 ± 4.4 y); mice: C57BL/6NCr, 2-month and 10-month-old · immunofluorescence of dictyate-arrested oocytes in frozen sections · per-oocyte REC8 reduced ~24% and SMC1B reduced ~38% in older vs younger women (p < 0.01, Student’s t-test); R² = 0.70 (REC8) and 0.62 (SMC1B) for linear regression with age · mitotic cohesins (SMC3, RAD21, SMC1A) unchanged with age · first direct human protein-level evidence for age-related meiotic cohesin loss · archive status: downloaded ↩
doi:10.1016/j.cub.2019.09.006 · Zielinska AP, Bellou E, Sharma N et al. · Current Biology 2019;29(23):3749–3765 · in-vivo + super-resolution imaging (AiryScan, STED) · n=35,700 kinetochores across mouse (14 young 8-wk, 29 old 60–64-wk FVB/N), pig, and human (17 younger ≤33 y, 32 older >34 y) MII eggs · centromeric CENP-A decompacts with age; inner and outer kinetochore regions fragment into multiple lobes in >30% of MII kinetochores of aged women and mice (mouse 60+ weeks: ~60% fragmented; human >34 y: ~40% fragmented vs ~25% in ≤33 y, p < 0.01); acute cohesin depletion in young eggs recapitulates the phenotype; fragmented kinetochores show increased merotelic microtubule attachment · archive status: downloaded ↩
doi:10.15252/embr.202357227 · Mihajlović AI, Byers C, Reinholdt L, FitzHarris G · EMBO Reports 2023;24(11) · in-vivo + imaging · model: aged mouse oocytes + human oocytes · demonstrates SAC insensitivity in meiosis-II is exacerbated by cohesin loss with age · archive status: pending ↩
doi:10.1093/biolre/ioy248 · Pasquariello R, Ermisch AF, Silva E et al. · Biology of Reproduction 2019;100(4):971–981 · in-vivo (mouse) + observational (human IVF-derived oocytes) · mitochondrial copy number, membrane potential, ROS, spindle abnormality characterization across age groups · archive status: not_oa — no-fulltext-access; quantitative claims (mouse copy number reduction, human compensatory elevation, specific ROS levels, spindle abnormality rates) not independently verified against source figures ↩
doi:10.1016/j.mito.2010.09.012 · Van Blerkom J · Mitochondrion 2011;11(5):797–813 · review · model: human oocyte/embryo · comprehensive review of mitochondrial role in oocyte competence and early development ↩
doi:10.1126/scitranslmed.3004925 · Titus S, Li F, Stobezki R et al. · Science Translational Medicine 2013;5(172):172ra21 · in-vivo (mouse BRCA1 KO) + observational (human BRCA1 mutation carriers, n=not-specified-in-abstract) · AMH reduction in young BRCA1-mutation carriers; DSB accumulation in mouse primordial follicles · archive status: pending ↩
doi:10.1093/humupd/dmz043 · Turan V, Oktay K · Human Reproduction Update 2020;26(1):43–57 · review · model: human BRCA mutation carriers + mouse models · archive status: pending ↩
doi:10.1016/j.advnut.2024.100273 · Shang Y, Song N, He R, Wu M · Advances in Nutrition 2024;15:100273 · systematic review and meta-analysis · n=2,617 participants across 20 parallel-controlled RCTs (antioxidants: CoQ10 10–1200 mg/d, melatonin 2–16 mg/d, myo-inositol 4 g/d, vitamin B/D/E, resveratrol 150 mg/d, antioxidant combinations); ovarian aging population (advanced maternal age >35 y or diminished ovarian reserve) · primary outcomes: live birth rate (OR 1.05, 95% CI 0.80–1.37, p = 0.74 — NOT significant); clinical pregnancy rate (OR 1.55, 95% CI 1.18–2.04, p = 0.002 — significant) · secondary outcomes: retrieved oocytes +0.98 (p < 0.0001), MII oocytes +0.47 (ns at p = 0.16), high-quality embryos +0.47 (p = 0.003) · CoQ10 30 mg/d × 3 months identified as optimal regimen in subgroup analysis · GRADE: live birth low quality; clinical pregnancy moderate quality · registered: PROSPERO CRD42022359529 ↩ ↩²
doi:10.1093/humupd/dmab044 · Buratini J, Dellaqua TT, Dal Canto M et al. · Human Reproduction Update 2022;28(3):315–336 · review · model: bovine + human · gap-junction disruption, FSH/AMH signaling dysregulation with aging · archive status: pending (doi:10.1093/humupd/dmab044) ↩
doi:10.1038/srep27991 · Zarate-Garcia L, Lane SIR, Merriman JA, Jones KT · Scientific Reports 2016 · in-vitro + FACS characterization · challenges DDX4-surface isolation claims for OSCs; concludes fixed-pool model supported · archive status: pending ↩
doi:10.1016/j.maturitas.2015.07.017 · Grieve KM, McLaughlin M, Dunlop CE, Telfer EE, Anderson RA · Maturitas 2015 · review · concludes no evidence OSCs contribute to human primordial follicle pool · archive status: pending ↩
doi:10.3390/ijms27051996 · Voros C et al. (16 authors) · International Journal of Molecular Sciences 2026 · review · translational fidelity as underrecognized driver of reproductive aging; ribosomal integrity and protein synthesis precision during oocyte maturation ↩

🧬 Aging Wiki

Explorer

oocytes